Locksley Announces Oversubscribed A$17 Million Placement Lead by U.S. Investors Funding to Accelerate Execution of Locksley's U.S. Mine to Market Strategy
SAN BERNARDINO, Calif., Dec. 8, 2025 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY/OTCQX: LKYRF/ADR: LKYLY) announced the successful completion of a heavily oversubscribed capital raising, securing firm commitments to raise approximately A$17...
DEEPX- Announces Ultra-Efficient AI Video Analytics Solution Based on AmpereOne® Platform
A New Architecture That Outperforms Traditional CPU + GPU Systems by a Wide Margin SANTA CLARA, Calif. and SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- DEEPX, a leader in ultra-low-power on-device AI semiconductors, announced on the 8th the...
51Talk Online Education Group Announces New Share Repurchase Program
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, today announced that its board of directors has...
51Talk Online Education Group Announces Third Quarter 2025 Results
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third...
Huya Announces January 7, 2026 Open Beta Launch for Goose Goose Duck Mobile in Chinese Mainland
GUANGZHOU, China, Dec. 8, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that the popular social deduction game Goose Goose Duck mobile, co‑published...
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated...
AGIBOT Announces the Rollout of Its 5,000th Mass-Produced Humanoid Robot
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- AGIBOT, a leading robotics company specializing in embodied intelligence, today announces the official roll-out of its 5,000th mass-produced humanoid robot at its factory. This milestone represents a step...
Connexus Travel Launches FIFA World Cup 26™ Content Series
Multi-platform rollout featuring match analysis, player profiles, team previews and travel guides as World Cup excitement intensifies post-draw HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Connexus Travel today announces the launch of its dedicated FIFA...
House of Rose Professional Announces 2026 World Tour of Break the Ceiling Touch the Sky® Summit
Partnership Plans to leverage the 2026 Tour now open for Americas, Europe, Middle East & Africa, India and World Editions of summit SINGAPORE, NEW YORK and LONDON, Dec. 8, 2025 /PRNewswire/ -- House of Rose Professional today announced the...
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...